Loading…
The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer
V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing...
Saved in:
Published in: | Cancer letters 2023-01, Vol.553, p.215996-215996, Article 215996 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3 |
---|---|
cites | cdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3 |
container_end_page | 215996 |
container_issue | |
container_start_page | 215996 |
container_title | Cancer letters |
container_volume | 553 |
creator | Liu, Bei Cheng, Li Gao, Honghao Zhang, Jiale Dong, Yanxin Gao, Wenda Yuan, Shunzong Gong, Taiqian Huang, Wenrong |
description | V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer.
•Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond. |
doi_str_mv | 10.1016/j.canlet.2022.215996 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2734167514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383522004839</els_id><sourcerecordid>2734167514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</originalsourceid><addsrcrecordid>eNp9kU9v1DAUxC1ERZeFb4CQJS5csvW_xDYHJFRBWakSh7ZcLcd-oV4l8WI7SPvt8SqFAwdO7_KbeaMZhN5QsqOEdleHnbPzCGXHCGM7Rlutu2doQ5VkjdSKPEcbwolouOLtJXqZ84EQ0grZvkCXvOOCSyU36PH-EXAf4hh_nHAc8Pe7_Y34gPfTcQzOlhDnjIeYcKlYSWDLBHM5g2GalhmaCXywBTwO8zDaabIlphP2IYPNkLGdPa4xHaRX6GKwY4bXT3eLHr58vr_-2tx-u9lff7ptHNekNFz2jHDv2k7YbiAwUEUY9NopaG1HvBJaEiF72nPnqR2U09rKASzzyirn-Ba9X32PKf5cIBczhexgHO0MccmGSS5oJ1sqKvruH_QQlzTXdGdKC6pZzbJFYqVcijknGMwxhcmmk6HEnJcwB7MuYc5LmHWJKnv7ZL70taS_oj_VV-DjCkBt41eAZLILUKvyIYErxsfw_w-_AV6Ym90</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2739419220</pqid></control><display><type>article</type><title>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</title><source>ScienceDirect Journals</source><creator>Liu, Bei ; Cheng, Li ; Gao, Honghao ; Zhang, Jiale ; Dong, Yanxin ; Gao, Wenda ; Yuan, Shunzong ; Gong, Taiqian ; Huang, Wenrong</creator><creatorcontrib>Liu, Bei ; Cheng, Li ; Gao, Honghao ; Zhang, Jiale ; Dong, Yanxin ; Gao, Wenda ; Yuan, Shunzong ; Gong, Taiqian ; Huang, Wenrong</creatorcontrib><description>V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer.
•Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2022.215996</identifier><identifier>PMID: 36343787</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Ablation ; Amino acids ; Animals ; Bacteria ; Biology ; Biomarkers ; Body fat ; By products ; Cancer ; Cell activation ; Cell differentiation ; Complement activation ; Complement component C3 ; Gram-positive bacteria ; Growth factors ; Hemophagocytic lymphohistiocytosis ; Homeostasis ; Humans ; Immune checkpoint ; Immune checkpoint inhibitors ; Immunoglobulins ; Inflammatory diseases ; Kinases ; Liver ; Lymphocytes T ; Macrophage activation syndrome ; Macrophages ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Neoplasms - therapy ; Opsonization ; Pathogens ; Phagocytosis ; Proteins ; Receptors, Complement - metabolism ; Tumor necrosis factor-TNF ; Tumor-associated macrophages ; VSIG4</subject><ispartof>Cancer letters, 2023-01, Vol.553, p.215996-215996, Article 215996</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><rights>2022. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</citedby><cites>FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</cites><orcidid>0000-0002-8981-0397</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36343787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Cheng, Li</creatorcontrib><creatorcontrib>Gao, Honghao</creatorcontrib><creatorcontrib>Zhang, Jiale</creatorcontrib><creatorcontrib>Dong, Yanxin</creatorcontrib><creatorcontrib>Gao, Wenda</creatorcontrib><creatorcontrib>Yuan, Shunzong</creatorcontrib><creatorcontrib>Gong, Taiqian</creatorcontrib><creatorcontrib>Huang, Wenrong</creatorcontrib><title>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer.
•Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond.</description><subject>Ablation</subject><subject>Amino acids</subject><subject>Animals</subject><subject>Bacteria</subject><subject>Biology</subject><subject>Biomarkers</subject><subject>Body fat</subject><subject>By products</subject><subject>Cancer</subject><subject>Cell activation</subject><subject>Cell differentiation</subject><subject>Complement activation</subject><subject>Complement component C3</subject><subject>Gram-positive bacteria</subject><subject>Growth factors</subject><subject>Hemophagocytic lymphohistiocytosis</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunoglobulins</subject><subject>Inflammatory diseases</subject><subject>Kinases</subject><subject>Liver</subject><subject>Lymphocytes T</subject><subject>Macrophage activation syndrome</subject><subject>Macrophages</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Neoplasms - therapy</subject><subject>Opsonization</subject><subject>Pathogens</subject><subject>Phagocytosis</subject><subject>Proteins</subject><subject>Receptors, Complement - metabolism</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor-associated macrophages</subject><subject>VSIG4</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU9v1DAUxC1ERZeFb4CQJS5csvW_xDYHJFRBWakSh7ZcLcd-oV4l8WI7SPvt8SqFAwdO7_KbeaMZhN5QsqOEdleHnbPzCGXHCGM7Rlutu2doQ5VkjdSKPEcbwolouOLtJXqZ84EQ0grZvkCXvOOCSyU36PH-EXAf4hh_nHAc8Pe7_Y34gPfTcQzOlhDnjIeYcKlYSWDLBHM5g2GalhmaCXywBTwO8zDaabIlphP2IYPNkLGdPa4xHaRX6GKwY4bXT3eLHr58vr_-2tx-u9lff7ptHNekNFz2jHDv2k7YbiAwUEUY9NopaG1HvBJaEiF72nPnqR2U09rKASzzyirn-Ba9X32PKf5cIBczhexgHO0MccmGSS5oJ1sqKvruH_QQlzTXdGdKC6pZzbJFYqVcijknGMwxhcmmk6HEnJcwB7MuYc5LmHWJKnv7ZL70taS_oj_VV-DjCkBt41eAZLILUKvyIYErxsfw_w-_AV6Ym90</recordid><startdate>20230128</startdate><enddate>20230128</enddate><creator>Liu, Bei</creator><creator>Cheng, Li</creator><creator>Gao, Honghao</creator><creator>Zhang, Jiale</creator><creator>Dong, Yanxin</creator><creator>Gao, Wenda</creator><creator>Yuan, Shunzong</creator><creator>Gong, Taiqian</creator><creator>Huang, Wenrong</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8981-0397</orcidid></search><sort><creationdate>20230128</creationdate><title>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</title><author>Liu, Bei ; Cheng, Li ; Gao, Honghao ; Zhang, Jiale ; Dong, Yanxin ; Gao, Wenda ; Yuan, Shunzong ; Gong, Taiqian ; Huang, Wenrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Ablation</topic><topic>Amino acids</topic><topic>Animals</topic><topic>Bacteria</topic><topic>Biology</topic><topic>Biomarkers</topic><topic>Body fat</topic><topic>By products</topic><topic>Cancer</topic><topic>Cell activation</topic><topic>Cell differentiation</topic><topic>Complement activation</topic><topic>Complement component C3</topic><topic>Gram-positive bacteria</topic><topic>Growth factors</topic><topic>Hemophagocytic lymphohistiocytosis</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunoglobulins</topic><topic>Inflammatory diseases</topic><topic>Kinases</topic><topic>Liver</topic><topic>Lymphocytes T</topic><topic>Macrophage activation syndrome</topic><topic>Macrophages</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Neoplasms - therapy</topic><topic>Opsonization</topic><topic>Pathogens</topic><topic>Phagocytosis</topic><topic>Proteins</topic><topic>Receptors, Complement - metabolism</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor-associated macrophages</topic><topic>VSIG4</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Cheng, Li</creatorcontrib><creatorcontrib>Gao, Honghao</creatorcontrib><creatorcontrib>Zhang, Jiale</creatorcontrib><creatorcontrib>Dong, Yanxin</creatorcontrib><creatorcontrib>Gao, Wenda</creatorcontrib><creatorcontrib>Yuan, Shunzong</creatorcontrib><creatorcontrib>Gong, Taiqian</creatorcontrib><creatorcontrib>Huang, Wenrong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Bei</au><au>Cheng, Li</au><au>Gao, Honghao</au><au>Zhang, Jiale</au><au>Dong, Yanxin</au><au>Gao, Wenda</au><au>Yuan, Shunzong</au><au>Gong, Taiqian</au><au>Huang, Wenrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2023-01-28</date><risdate>2023</risdate><volume>553</volume><spage>215996</spage><epage>215996</epage><pages>215996-215996</pages><artnum>215996</artnum><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer.
•Expression of VSIG4 and potential regulatory mechanisms in macrophages.•Role of VSIG4 in regulating macrophage phagocytosis.•Role of VSIG4 in complement pathway and T cell activation.•Role of VSIG4 in tumor microenvironment.•sVSIG4 in diseases related to macrophage activation and beyond.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>36343787</pmid><doi>10.1016/j.canlet.2022.215996</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8981-0397</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0304-3835 |
ispartof | Cancer letters, 2023-01, Vol.553, p.215996-215996, Article 215996 |
issn | 0304-3835 1872-7980 |
language | eng |
recordid | cdi_proquest_miscellaneous_2734167514 |
source | ScienceDirect Journals |
subjects | Ablation Amino acids Animals Bacteria Biology Biomarkers Body fat By products Cancer Cell activation Cell differentiation Complement activation Complement component C3 Gram-positive bacteria Growth factors Hemophagocytic lymphohistiocytosis Homeostasis Humans Immune checkpoint Immune checkpoint inhibitors Immunoglobulins Inflammatory diseases Kinases Liver Lymphocytes T Macrophage activation syndrome Macrophages Mice Mice, Inbred C57BL Mice, Knockout Neoplasms - therapy Opsonization Pathogens Phagocytosis Proteins Receptors, Complement - metabolism Tumor necrosis factor-TNF Tumor-associated macrophages VSIG4 |
title | The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20biology%20of%20VSIG4:%20Implications%20for%20the%20treatment%20of%20immune-mediated%20inflammatory%20diseases%20and%20cancer&rft.jtitle=Cancer%20letters&rft.au=Liu,%20Bei&rft.date=2023-01-28&rft.volume=553&rft.spage=215996&rft.epage=215996&rft.pages=215996-215996&rft.artnum=215996&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2022.215996&rft_dat=%3Cproquest_cross%3E2734167514%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-37b203dc564a6f0ef1802eb9c8e5a60d8497047b1b3cd1af8c99a7fea2d8a8cc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2739419220&rft_id=info:pmid/36343787&rfr_iscdi=true |